Martine Rothblatt Buys Shares in United Therapeutics

Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation, made a significant stock purchase on June 22, 2026. Rothblatt bought 9,500 shares of the company at an average price of $138.67 each, amounting to a total investment of approximately $1.32 million. This transaction was not part of a pre-planned trading program.

Other Institutional Activity in United Therapeutics

BlackRock, Inc. increased its holdings in United Therapeutics by 228,883 shares, bringing its total to 5,399,649 shares valued at about $3.20 billion, marking a 4.4% increase. Avoro Capital Advisors LLC also expanded its position slightly by adding 23,940 shares, for a total of 2,630,000 shares worth $1.56 billion, a 0.9% increase. Wellington Management Group LLP, however, reduced its stake by 177,245 shares, leaving it with 2,264,247 shares valued at $1.34 billion, representing a 7.3% decrease. Meanwhile, Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both initiated new positions, holding 2,003,742 and 1,957,539 shares, respectively.

United Therapeutics Corporation Stock Up 6.1%

Shares of NasdaqGS:UTHR traded near $544.40 on Wednesday. The company boasts a market capitalization of $22.85 billion and a P/E ratio of 19.91, with a forward P/E of 16.94. The stock's beta is 0.573, indicating lower volatility than the market. United Therapeutics has seen a 52-week low of $272.12 and a high of $609.35. The 50-day moving average is $565.40, and the 200-day moving average is $497.47. The company maintains a strong liquidity position with a current ratio of 4.79 and a quick ratio of 4.12.

Recent Earnings

In the most recent earnings report, United Therapeutics posted revenue of approximately $3.17 billion, though it experienced a slight revenue decline of 1.6%. The company achieved a net margin of 40.6% and a return on equity of 20.3%. The next earnings announcement is scheduled for July 29, 2026.

Analysts Set New Price Targets

On May 7, 2026, RBC Capital maintained its buy rating on United Therapeutics with a price target of $701. Wells Fargo upgraded the stock to a buy with a target of $738. Meanwhile, Morgan Stanley maintained a hold rating with a target of $519 set on April 10, 2026. The consensus among 13 analysts is a buy recommendation, with an average target price of $665.23.

About United Therapeutics

United Therapeutics Corporation, headquartered in Silver Spring, Maryland, operates in the healthcare sector, specifically within the drug manufacturing industry. The company focuses on developing and commercializing treatments for chronic and life-threatening conditions, including pulmonary arterial hypertension and neuroblastoma. Under the leadership of CEO Dr. Martine Rothblatt, the company employs about 1,400 people and continues to innovate in the field of regenerative medicine and organ transplantation.

Bottom Line

Martine Rothblatt's recent purchase of United Therapeutics shares underscores her confidence in the company's future. While insider transactions like this can signal optimism, it's important to remember that they are just one piece of the puzzle. Investors often watch such moves closely, but it's crucial to consider the broader financial landscape and company fundamentals.